Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Screening for prostate cancer.

Shandra S Wilson1, E David Crawford

  • 1Department of Urologic Oncology, Anschutz Cancer Center, Denver, CO, USA. shandra.wilson@uchsc.edu

Clinical Prostate Cancer
|July 29, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate Cancer.

Clinical genitourinary cancer·2026
Same author

Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.

JCO oncology practice·2024
Same author

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.

Cancer·2024
Same author

Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.

Cancer medicine·2024
Same author

Editorial Comment on "Should Military Veterans Be Classified as High Risk for Prostate Cancer Screening? A Systematic Review and Meta-analysis".

Urology·2024
Same journal

A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.

Clinical prostate cancer·2005
Same journal

Orbital metastasis from prostate cancer: an atypical case of neuroendocrine dedifferentiation during progression from hormone-sensitive to refractory stage.

Clinical prostate cancer·2005
Same journal

Recent trends in surgical treatment of localized prostate cancer.

Clinical prostate cancer·2005
Same journal

Molecular effects of the isoflavonoid genistein in prostate cancer.

Clinical prostate cancer·2005
Same journal

Prostate-specific membrane antigen vaccines: naked DNA and protein approaches.

Clinical prostate cancer·2005
Same journal

Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer.

Clinical prostate cancer·2005
See all related articles

Prostate cancer screening is crucial for reducing disease mortality. Early detection through screening can significantly decrease the number of deaths caused by this prevalent cancer.

Area of Science:

  • Oncology
  • Public Health
  • Medical Screening

Background:

  • Prostate cancer is a leading cause of cancer death in Western countries.
  • It affects a significant number of men annually in the United States.
  • Healthcare strategies to reduce disease impact include prevention, screening, and improved treatments.

Purpose of the Study:

  • To summarize the screening aspects of prostate cancer.
  • To highlight the importance of early detection in managing prostate cancer.
  • To discuss theoretical healthcare measures for decreasing prostate cancer morbidity and mortality.

Main Methods:

  • This summary focuses on reviewing existing literature and data regarding prostate cancer screening.
  • Analysis of epidemiological data on prostate cancer prevalence and mortality.

Related Experiment Videos

  • Evaluation of theoretical healthcare interventions for prostate cancer management.

    • Main Results:

    • Prostate cancer screening is a key strategy for reducing mortality rates.
    • Effective screening protocols can transform lethal prostate cancer into a manageable chronic condition.
    • Understanding screening's role is vital for public health initiatives.

    Conclusions:

    • Screening for prostate cancer is a critical component of reducing its impact.
    • Further research and implementation of screening programs are essential.
    • Comprehensive strategies involving screening are necessary to combat prostate cancer effectively.